Merck & Co., Inc. is 160.1x more valuable than Rapport Therapeutics, Inc. by market capitalization ($294.03 B vs $1.84 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RAPP | MRK |
|---|---|---|
| Market cap | $1.84 B | $294.03 B |
| US-listed rank | #2176 | #45 |
| Revenue (latest FY) | - | $65.01B |
| Net income (latest FY) | -$111.48M | $18.25B |
| Net margin | - | 28.1% |
| P/E (trailing FY) | - | 16.1 |
| SEC filings | 197 | 996 |
Merck & Co., Inc. is 160.1x more valuable than Rapport Therapeutics, Inc. by market capitalization ($294.03 B vs $1.84 B).
Full pages: Rapport Therapeutics, Inc. and Merck & Co., Inc., or browse the full rankings.